Levicept Ltd is a UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. The company is progressing LEVI-04 to phase I clinical trials to test its efficacy and safety in patients with osteoarthritis.
With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability.
With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability.
Location: United Kingdom, England, Sandwich
Employees: 11-50
Total raised: $20M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Gilde Heal... | gildehealt... |
| - | Advent Lif... | adventls.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.10.2014 | - | $20M | - |
Mentions in press and media 2
| Date | Title | Description |
| 08.10.2014 | Levicept emerges from Pfizer's R&D ashes with $20M and a new pain drug | Pfizer's ($PFE) 2011 move to close a sprawling R&D campus in Sandwich, U.K., put more than 2,000 researchers out of work and brought an abrupt end to scores of development projects. But one of those investigators, Simon Westbrook, never... |
| 07.10.2014 | Levicept Ltd closes £10 million financing round | Sandwich, UK – Levicept Ltd., a biopharmaceutical company focused on the development of LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc) for chronic pain indications, announces that it has closed a £10 million Series A financ... |